|
Asenapine (USAN, rINNM and BANM;〔Truven Health Analytics, Inc. MARTINDALE - The Complete Drug Reference (Internet) (2013 Sep 30 ). Greenwood Village, CO: Thomsen Healthcare; 2013.〕 trade names Saphris (AU, US, RU), Sycrest (EU, UK)) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA approved the manufacturer's NDA in August 2009. It was chemically derived via altering the chemical structure of the tetracyclic (''atypical'') antidepressant, mianserin. == Medical uses == Asenapine has been approved by the FDA for the acute treatment of adults with schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. In Australia asenapine's approved (and also listed on the PBS) indications include the following: * Schizophrenia * Treatment, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder * Maintenance treatment, as monotherapy, of bipolar I disorder In the European Union and the UK asenapine is only licensed for use as a treatment for acute mania in bipolar I disorder.〔〔 Absorbed readily if administered sublingually, asenapine is poorly absorbed when swallowed. It appears to be less efficacious than other antipsychotics in the treatment of schizophrenia,〔 although its all-cause discontinuation rate is moderate.〔 As for its efficacy in the treatment of acute mania, a recent meta-analysis showed that it produces comparatively small improvements in manic symptoms in patients with acute mania and mixed episodes than most other antipsychotic drugs (with the exception of ziprasidone) such as risperidone and olanzapine. Drop-out rates (in clinical trials) were also unusually high with asenapine. According to a post-hoc analysis of two 3-week clinical trials it may possess some antidepressant effects in patients with acute mania or mixed episodes. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Asenapine」の詳細全文を読む スポンサード リンク
|